Google
MRK 株価分析 — MERCK & COMPANY INC (Healthcare >> Drug Manufacturers - General)
MRK に関するよくある質問
MRKのPER（株価収益率）は？
MERCK & COMPANY INC（MRK）は現在PER 23.32倍で取引されています。
MRKのROE（自己資本利益率）は？
MERCK & COMPANY INCのROEは19.48%です。
MRKの配当利回りは？
MERCK & COMPANY INCの配当利回りは2.52%です。
MRKの品質スコア（Quality Score）は？
当社のAIはMRKの総合財務品質を100点中69点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
MRKは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
MRKはどのセクターに属しますか？
MERCK & COMPANY INCはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE市場）
MRK AI Analysis Summary
Our AI summary for MRK: MERCK & COMPANY INC (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 23.32, ROE of 19.48%, a dividend yield of 2.52%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 130.20
Price
0.41
(0.32%)
Day Change
|
|
|---|
MRK, ファンダメンタルスコアはok ( ファンダメンタル = 69) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
848
|
| Magic Formula Rank by ROE |
848
|
| Magic Formula Rank by ROIC |
1077
|
| Price | 130.20 |
| PBV / Sector |
6.69 / 2.68
|
| Earning Per Share | 3.79 |
| PE / Sector |
23.32 / 27.65
|
| PEG or PE/Growth / Sector |
0.02 / 0.28
GREAT
|
| Average 1M Daily Value |
1,091.58 M
GREAT
|
| Average 1W Daily Value |
1,052.56 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
54% |
| ポイントになる統計 |
|
75% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:11 |
| Symbol | MRK |
| Name | MERCK & COMPANY INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 2,469.82 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 307,246.17 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
Phone: 908 740 4000
Website: https://www.merck.com
Employees: 73,000
Description: Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
